Vicore Pharma AB

We are thrilled to announce the initiation of the global, randomized Phase 2b ASPIRE trial, a pivotal step forward in our ongoing efforts to develop innovative treatments for idiopathic pulmonary fibrosis (#IPF). It is especially fitting that we are launching this important trial during Pulmonary Fibrosis Awareness Month, highlighting our dedication to raising awareness and finding solutions for these debilitating diseases. Our collaboration with PSI CRO AG is central to this undertaking, bringing together our shared expertise and commitment to making a difference in the lives of patients affected by IPF. You can find more information on the trial here: https://lnkd.in/e47PThKP #PFMonth #PulmonaryFibrosisAwarenessMonth #BlueUp4PF #clincialresearch #buloxibutid #Vicore

This week, members of the Vicore team presented exciting new data at the European Respiratory Society Annual World Congress 2024 in Vienna. Vicore’s presentations further describe the power of buloxibutid’s upstream tissue-repair mechanism and highlight the patient-friendly design of the Phase 2b ASPIRE trial investigating buloxibutid in #IPF.  Check out the e-posters available on our website! https://lnkd.in/exKB4KG3    #ERS #EuropeanRespiratorySociety #buloxibutid #Vicore

An exciting week at the 8th Annual IPF Summit has come to an end, it has been a week of great interactions and learnings. Vicore CMO Professor Bertil E. Lindmark MD, PhD did a presentation on clinical development within #IPF, the importance of reducing fibrosis and promoting alveolar healing to increase of lung function, as seen in our phase 2a AIR trial. #IPFsummit #Vicore #buloxibutid

Looking to make a difference in the lives of patients with #ipf? Come join our dynamic team at Vicore and be a part of this exciting new stage of growth! We are currently looking to hire Clinical Science Liaisons (#CSLs) in the US and Europe. Read more about these opportunities and apply here: US: https://lnkd.in/d69CWmcn UK: https://lnkd.in/dqd52Sxr Germany/Austria: https://lnkd.in/d86Gm5XS #TeamVicore #hiring

Come join our fantastic team! We are looking for a QA Manager GMP to our office in Hørsholm, Denmark. Read more about the position and apply here: https://lnkd.in/d2FnpeTf

Vicore Pharma AB is pleased to announce positive final results from the Phase 2a AIR trial demonstrating that buloxibutid improves lung function over 36 weeks in patients with idiopathic pulmonary fibrosis (#IPF). These encouraging results were presented yesterday by Toby Maher, Keck School of Medicine of USC, as a late-breaking oral session at the American Thoracic Society International Congress (#ATS2024). Vicore will be discussing the results in more detail during a webinar on Wednesday 5/22 at 10:00 ET/16:00 CET. You can register for the webinar here: https://lnkd.in/eKp8xYGj #pulmonaryfibrosis #biotechnews #respiratory #clinicaldata

Vicore at the Clinical Trials booth at #ATS2024 in San Diego. Come see us, we’re presenting phase 2a data and starting phase 2b. Jimmy Nolin, Ph.D. Åsa Magnusson, Ahmed Mousa, Jimmie Hofman, Jessica Shull, Cecilia Ganslandt, Johan Raud, May-Lill Garly, MD PhD, Professor Bertil E. Lindmark MD, PhD

We are pleased to announce that Mikael Nygård, VP Operations and Corporate Strategy, will present recent and upcoming activities at Aktiespararnas digital life science event today. Register to the event in the link below and tune in at 15:20 CET: https://lnkd.in/g_7YRn9J

Vicore is pleased to announce that our digital therapy, Almee, has received Breakthrough Device Designation from the FDA. Almee is the first digital therapy to address anxiety and quality of life in patients living with pulmonary fibrosis. The Breakthrough Program designates those medical devices that are evaluated as providing a more effective treatment for life-threatening or irreversibly debilitating diseases. Wonderful work from the team and of course, very impressive work from Alex Therapeutics.

Our CEO, Ahmed Mousa, was recently featured on the Drug Discovery World 'In Conversation With' podcast, where he discussed Vicore Pharma AB ATRAG formulations for rare lung diseases. Listen to the episode here as we explore the potential of this new class of drug candidates: bit.ly/4cb1hh2 #VicorePharma #IPF #ATRAGs